Anti-Fibrinolytic Drugs - New Zealand

The Anti-Fibrinolytic Drugs market in New Zealand is forecasted to witness a revenue of NZD US$22.21m by 2024.
This is expected to exhibit an annual growth rate (CAGR 2024-2029) of 4.79%, leading to a market volume of NZD US$28.07m by 2029.
Comparatively, United States is projected to generate the highest revenue in the global market, amounting to US$9.86bn in 2024.
New Zealand's market for Anti-Fibrinolytic Drugs is witnessing a growing demand due to the rising prevalence of cardiovascular diseases in the country.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

The Anti-Fibrinolytic Drugs market in New Zealand has been showing a steady growth in recent years.

Customer preferences: The increasing prevalence of cardiovascular diseases and the rising geriatric population are the primary factors driving the growth of the Anti-Fibrinolytic Drugs market in New Zealand. Patients suffering from cardiovascular diseases require prolonged treatment, which results in a high demand for anti-fibrinolytic drugs. Additionally, the preference for minimally invasive surgeries has led to an increase in the use of anti-fibrinolytic drugs.

Trends in the market: The Anti-Fibrinolytic Drugs market in New Zealand is expected to witness significant growth in the coming years. The increasing investment in research and development activities, coupled with the rising demand for anti-fibrinolytic drugs, is expected to drive the market growth. Moreover, the launch of new drugs and the development of advanced drug delivery systems are expected to create new growth opportunities in the market.

Local special circumstances: New Zealand has a well-developed healthcare system, which provides easy access to healthcare services to the population. The government of New Zealand has implemented various initiatives to improve the healthcare system, which has led to an increase in the demand for anti-fibrinolytic drugs. Additionally, the increasing awareness about the benefits of anti-fibrinolytic drugs among healthcare professionals and patients is expected to drive the market growth.

Underlying macroeconomic factors: The growing population and the increasing prevalence of chronic diseases are the primary macroeconomic factors driving the growth of the Anti-Fibrinolytic Drugs market in New Zealand. Additionally, the rising healthcare expenditure and the increasing investment in research and development activities are expected to drive the market growth. However, the high cost of anti-fibrinolytic drugs and the stringent regulatory policies may hinder the market growth in the country.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.